Previous close | 94.46 |
Open | 94.20 |
Bid | 94.31 x 0 |
Ask | 94.32 x 0 |
Day's range | 94.07 - 94.37 |
52-week range | 79.19 - 94.52 |
Volume | |
Avg. volume | 527,963 |
Market cap | 192.512B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 24.06 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.30 (3.49%) |
Ex-dividend date | 07 Mar 2024 |
1y target est | N/A |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.